IntegraGen

GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.

The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology. 

Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.

The planned sequencing platform will be used for both exome and whole-genome sequencing research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry.

The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.

The hospital will use the new methods with jointly developed bioinformatic analysis techniques to rapidly interpret genomic data. 

IntegraGen will conduct sequencing for theNationalReferenceCenterand the microbiological collections at Institut Pasteur.

Genoma will commercialize the Arisk test outside the US and will provide genetic consulting services and diagnostics services to children with ASD and their parents.

The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.

The signatures involve a panel of genes that help researchers to distinguish between benign and malignant liver tumors and identify histological subtypes

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.